爱朋医疗(300753) - 2022 Q1 - 季度财报

Report Cover and Disclaimer Important Content Notice This quarterly report is unaudited, but the company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the report content, and assume corresponding legal responsibilities - The Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, free from false records, misleading statements, or major omissions[3] - The company's responsible person, head of accounting, and head of accounting department declare and guarantee the truthfulness, accuracy, and completeness of the financial information[3] - The first quarterly report is unaudited[4] I. Major Financial Data (1) Major Accounting Data and Financial Indicators The company's operating revenue for Q1 2022 decreased by 28.85% year-on-year, with net profit attributable to shareholders turning from profit to loss, a 157.05% decrease year-on-year, and basic earnings per share at -0.0872 CNY/share Major Accounting Data and Financial Indicators for Q1 2022 | Indicator | Current Period (CNY) | Prior Period (CNY) | Change from Prior Period | | :--- | :--- | :--- | :--- | | Operating Revenue | 72,794,357.61 | 102,316,781.63 | -28.85% | | Net Profit Attributable to Shareholders of Listed Company | -10,987,817.03 | 19,258,855.13 | -157.05% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Gains and Losses) | -10,948,474.02 | 18,778,459.93 | -158.30% | | Net Cash Flow from Operating Activities | -58,957,573.53 | -45,806,338.66 | -28.71% | | Basic Earnings Per Share | -0.0872 | 0.1528 | -157.07% | | Diluted Earnings Per Share | -0.0872 | 0.1528 | -157.07% | | Weighted Average Return on Net Assets | -1.42% | 2.57% | -3.99% | | End of Reporting Period | End of Previous Year | Change from End of Previous Year | | | Shareholders' Equity Attributable to Shareholders of Listed Company | 773,281,352.48 | 779,618,094.51 | -0.81% | | Total Assets | 870,046,130.30 | 899,058,120.32 | -3.23% | (2) Non-Recurring Gains and Losses Items and Amounts Total non-recurring gains and losses for this period amounted to -39,343.01 CNY, primarily including government subsidies, non-operating income and expenses, and other profit and loss items, after deducting income tax and minority interest impacts Non-Recurring Gains and Losses Items and Amounts for Q1 2022 | Item | Amount for Current Period (CNY) | Description | | :--- | :--- | :--- | | Government Subsidies Included in Current Period's Profit and Loss | 344,933.33 | | | Other Non-Operating Income and Expenses Apart from the Above | -554,203.96 | | | Other Profit and Loss Items Meeting the Definition of Non-Recurring Gains and Losses | 230,414.57 | | | Less: Income Tax Impact | 20,091.62 | | | Minority Interest Impact (After Tax) | 40,395.33 | | | Total | -39,343.01 | -- | (3) Changes and Reasons for Major Accounting Data and Financial Indicators The company's balance sheet, income statement, and cash flow statement show significant changes across multiple indicators, with notable shifts in assets, expenses, and financing activities Balance Sheet Item Changes (Over 30% Fluctuation) | Item | March 31, 2022 (CNY) | December 31, 2021 (CNY) | Change Percentage | Explanation for Changes Over 30% | | :--- | :--- | :--- | :--- | :--- | | Cash and Bank Balances | 163,370,955.50 | 274,662,850.56 | -40.52% | Idle raised funds used to purchase bank wealth management products | | Notes Receivable | 7,845,220.80 | 1,595,362.15 | 391.75% | Some customers settled with bank acceptance bills | | Prepayments | 14,904,487.66 | 8,243,020.75 | 80.81% | Some suppliers settled with advance payments | | Other Receivables | 14,997,691.54 | 6,797,834.19 | 120.62% | Increase in petty cash | | Other Current Assets | 50,653,796.38 | 2,946,768.68 | 1,618.96% | Idle raised funds used to purchase bank wealth management products | | Fixed Assets | 157,668,213.43 | 102,317,147.47 | 54.10% | Construction in progress transferred to fixed assets | | Construction in Progress | 19,537,278.91 | 70,490,150.49 | -72.28% | Construction in progress transferred to fixed assets | | Other Non-Current Assets | 2,033,050.00 | 3,692,787.99 | -44.95% | Transferred to intangible assets | | Short-Term Borrowings | 10,000,000.00 | - | - | New short-term borrowings | | Notes Payable | 3,000,000.00 | 2,000,000.00 | 50.00% | Increase in notes payable for goods | | Accounts Payable | 13,982,321.00 | 25,762,903.63 | -45.73% | Previous period's unpaid amounts paid in current period | | Contract Liabilities | 6,920,781.78 | 4,501,500.72 | 53.74% | Advance receipts for goods | | Employee Benefits Payable | 6,317,180.64 | 25,794,850.06 | -75.51% | Year-end bonus accrued at end of previous period distributed | | Other Payables | 5,309,414.18 | 9,503,744.08 | -44.13% | Previous period's accrued unpaid amounts paid in current period | | Other Current Liabilities | 879,513.01 | 502,516.27 | 75.02% | VAT corresponding to contract liabilities | Income Statement Item Changes (Over 30% Fluctuation) | Item | Jan-Mar 2022 (CNY) | Jan-Mar 2021 (CNY) | Change Percentage | Explanation for Changes Over 30% | | :--- | :--- | :--- | :--- | :--- | | Selling Expenses | 25,998,144.89 | 19,579,869.91 | 32.78% | Increased market investment and employee compensation | | R&D Expenses | 10,224,739.54 | 5,755,136.68 | 77.66% | Increased R&D investment, increased R&D office rent | | Financial Expenses | 256,497.88 | -230,937.24 | 211.07% | Increase in unrecognized financing expenses from leases | | Investment Income | -670,523.76 | 104,117.43 | -744.01% | Investment income recognized from long-term investment losses | | Non-Operating Income | 308,048.89 | 568,811.76 | -45.84% | Decrease in government subsidies | | Non-Operating Expenses | 554,795.82 | 2,670.34 | 20,676.22% | Donations in current period | Cash Flow Statement Item Changes (Over 30% Fluctuation) | Item | Jan-Mar 2022 (CNY) | Jan-Mar 2021 (CNY) | Change Percentage | Explanation for Changes Over 30% | | :--- | :--- | :--- | :--- | :--- | | Net Cash Flow from Financing Activities | 9,563,006.67 | -96,085.00 | 10,052.65% | New short-term borrowings | II. Shareholder Information (1) Total Number of Common Shareholders, Preferred Shareholders with Restored Voting Rights, and Top Ten Shareholders' Holdings As of the end of the reporting period, the company had 11,623 common shareholders. Among the top ten shareholders, Wang Ningyu and Zhang Zhihui were the top two, holding 36.15% and 14.20% respectively, with portions of their shares pledged - As of the end of the reporting period, the total number of common shareholders was 11,623, with no preferred shareholders with restored voting rights[12] Top 10 Shareholders' Holdings | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held (Shares) | Number of Restricted Shares Held (Shares) | Share Status | Quantity (Shares) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Wang Ningyu | Domestic Natural Person | 36.15% | 45,567,811 | 34,175,858 | Pledged | 16,291,760 | | Zhang Zhihui | Domestic Natural Person | 14.20% | 17,901,928 | 13,426,446 | Pledged | 3,324,000 | | Ye Jianli | Domestic Natural Person | 1.54% | 1,944,788 | 1,458,591 | - | - | | Shanghai Guohong Zhiyan Venture Capital Partnership (Limited Partnership) | Other | 1.48% | 1,869,905 | 0 | - | - | | Yin Xuezhi | Domestic Natural Person | 1.14% | 1,431,662 | 0 | - | - | | Nantong Jianhua Venture Capital Partnership (Limited Partnership) | Other | 0.88% | 1,105,844 | 0 | - | - | | Guan Jifeng | Domestic Natural Person | 0.84% | 1,055,795 | 791,846 | Pledged | 777,300 | | Gu Aijun | Domestic Natural Person | 0.58% | 734,304 | 550,728 | Pledged | 734,304 | | Sun Zuwei | Domestic Natural Person | 0.58% | 724,875 | 0 | Pledged | 684,000 | | Li Chao | Domestic Natural Person | 0.51% | 644,640 | 0 | - | - | - Company shareholders Li Chao and Yang Kexin collectively hold shares through ordinary securities accounts and margin trading and securities lending accounts[13] (2) Total Number of Preferred Shareholders and Top 10 Preferred Shareholders' Holdings The company has no preferred shareholders - The company has no preferred shareholders[14] (3) Changes in Restricted Shares During the reporting period, the total number of restricted shares slightly decreased, mainly due to changes in executive lock-up shares, with Guan Jifeng's restricted shares decreasing by 71,835 shares, and Li Qing and Wang Xianrong's restricted shares slightly adjusted due to rounding Changes in Restricted Shares | Shareholder Name | Restricted Shares at Beginning of Period (Shares) | Restricted Shares Released in Current Period (Shares) | Restricted Shares Increased in Current Period (Shares) | Restricted Shares at End of Period (Shares) | Reason for Restriction | Proposed Release Date | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Wang Ningyu | 34,175,858 | 0 | 0 | 34,175,858 | Executive Lock-up Shares | During tenure, no more than 25% of total shares held by the company can be transferred annually; no transfers within half a year after resignation | | Zhang Zhihui | 13,426,446 | 0 | 0 | 13,426,446 | Executive Lock-up Shares | Same as above | | Ye Jianli | 1,458,591 | 0 | 0 | 1,458,591 | Executive Lock-up Shares | Same as above | | Guan Jifeng | 863,681 | 71,835 | 0 | 791,846 | Executive Lock-up Shares | Same as above | | Gu Aijun | 550,728 | 0 | 0 | 550,728 | Executive Lock-up Shares | Same as above | | Miao Fei | 159,476 | 0 | 0 | 159,476 | Executive Lock-up Shares | Same as above | | Yuan Dongqi | 159,476 | 0 | 0 | 159,476 | Executive Lock-up Shares | Same as above | | Li Qing | 175,422 | 0 | 1 | 175,423 | Executive Lock-up Shares | Same as above | | Wang Xianrong | 137,651 | 0 | 0 | 137,650 | Executive Lock-up Shares | Same as above | | Total | 51,107,329 | 71,836 | 1 | 51,035,494 | -- | -- | - The change in Guan Jifeng's restricted shares is due to changes in executive lock-up shares; the discrepancy in Li Qing and Wang Xianrong's restricted shares is due to rounding by China Securities Depository and Clearing Corporation Limited when calculating executive lock-up share data[16] III. Other Important Matters Reasons for Decline in Operating Revenue The company's Q1 2022 operating revenue decreased by 28.85% year-on-year, primarily due to the Spring Festival holiday, COVID-19 controls in Shanghai, Guangdong, and Jiangsu affecting surgeries and outpatient visits, and the company's proactive reduction of agency product business - The first quarter is a sales off-season due to the Spring Festival holiday and logistics factors, resulting in relatively lower sales[17] - From February to March 2022, severe COVID-19 outbreaks in Shanghai, Guangdong, Jiangsu, and other provinces and cities led to a decrease in surgical volumes, affecting the use of microcomputer infusion pumps and other products; ENT outpatient visits declined, impacting offline sales of nasal care sprays; epidemic prevention and control measures affected new business development and existing business growth[17] - The company reduced its agency product business, with agency product revenue in Q1 2022 at 9.3379 million CNY, a 48.84% year-on-year decrease[17] Reasons for Decline in Net Profit The company's Q1 2022 net profit turned from profit to loss, decreasing by 157.05% year-on-year, primarily due to decreased operating revenue, a 77.66% increase in R&D expenses, a 32.78% increase in selling expenses, and a 4.6511 million CNY impact from equity incentive expenses - The company's operating revenue decreased by 28.85% year-on-year[17] - The company actively introduced R&D technical personnel, explored cutting-edge technology projects, increased investment in key R&D projects, and incurred new office rental expenses for the R&D center, leading to a 77.66% year-on-year increase in R&D expenses[17] - During the reporting period, the company increased advertising investment and marketing efforts on online e-commerce platforms, new media, and live streaming channels, fully leveraging the consumer attributes of nasal care sprays, resulting in a 32.78% year-on-year increase in selling expenses[17] - The impact of equity incentive expenses during the reporting period was 4.6511 million CNY[17] Shareholder Feedback Activity On March 31, 2022, the company announced the 'Nose Care Health Protection · Aipeng Medical Shareholder Feedback Activity,' offering two free bottles of Nosclear® Physiological Seawater Nasal Care Spray to all shareholders registered on the 2021 annual general meeting record date - The company launched the 'Nose Care Health Protection · Aipeng Medical Shareholder Feedback Activity,' offering two free bottles of Nosclear® Physiological Seawater Nasal Care Spray to eligible shareholders[18] Anti-Epidemic Donation Activity In response to expert calls and to fulfill social responsibility, Aipeng Medical and its subsidiary Nosclear actively participated in anti-epidemic donations, cumulatively donating over 160,000 bottles of Nosclear® Physiological Seawater Nasal Care Spray to support local epidemic prevention and control efforts - Aipeng Medical and its subsidiary Nosclear actively participated in anti-epidemic donation activities[20] - As of the announcement date, the company has cumulatively donated over 160,000 bottles of Nosclear® Physiological Seawater Nasal Care Spray through channels such as the China Siyuan Engineering Poverty Alleviation Foundation, local Centers for Disease Control and Prevention, Red Cross societies, and hospitals[20] IV. Quarterly Financial Statements (1) Financial Statements This section provides the company's consolidated balance sheet, consolidated income statement, and consolidated cash flow statement for Q1 2022, detailing the financial position, operating results, and cash flows at the end of the reporting period 1. Consolidated Balance Sheet As of March 31, 2022, the company's total assets were 870.05 million CNY, a 3.23% decrease from the beginning of the year; total current assets were 447.19 million CNY, and total non-current assets were 422.86 million CNY. Total liabilities were 96.33 million CNY, and total owners' equity was 773.71 million CNY Consolidated Balance Sheet (Summary) | Item | Ending Balance (CNY) | Beginning Balance (CNY) | | :--- | :--- | :--- | | Total Assets | 870,046,130.30 | 899,058,120.32 | | Total Current Assets | 447,189,315.83 | 484,206,529.26 | | Total Non-Current Assets | 422,856,814.47 | 414,851,591.06 | | Total Liabilities | 96,334,953.93 | 118,537,547.84 | | Total Owners' Equity | 773,711,176.37 | 780,520,572.48 | 2. Consolidated Income Statement In Q1 2022, the company achieved total operating revenue of 72.79 million CNY and total operating costs of 86.01 million CNY, resulting in an operating loss of 12.31 million CNY. Net profit attributable to parent company owners was -10.99 million CNY Consolidated Income Statement (Summary) | Item | Amount for Current Period (CNY) | Amount for Prior Period (CNY) | | :--- | :--- | :--- | | I. Total Operating Revenue | 72,794,357.61 | 102,316,781.63 | | II. Total Operating Costs | 86,007,113.51 | 81,230,282.84 | | III. Operating Profit | -12,312,975.32 | 22,228,476.47 | | IV. Total Profit | -12,559,722.25 | 22,794,617.89 | | V. Net Profit | -11,460,471.11 | 19,691,763.50 | | Net Profit Attributable to Owners of the Parent Company | -10,987,817.03 | 19,258,855.13 | | VIII. Earnings Per Share (Basic/Diluted) | -0.0872 | 0.1528 | 3. Consolidated Cash Flow Statement In Q1 2022, net cash flow from operating activities was -58.96 million CNY, from investing activities was -62.10 million CNY, and from financing activities was 9.56 million CNY, with cash and cash equivalents balance at the end of the period being 162.77 million CNY Consolidated Cash Flow Statement (Summary) | Item | Amount for Current Period (CNY) | Amount for Prior Period (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -58,957,573.53 | -45,806,338.66 | | Net Cash Flow from Investing Activities | -62,097,328.20 | -72,486,370.77 | | Net Cash Flow from Financing Activities | 9,563,006.67 | -96,085.00 | | Net Increase in Cash and Cash Equivalents | -111,491,895.06 | -118,388,794.43 | | Cash and Cash Equivalents at End of Period | 162,770,955.50 | 270,169,579.52 | (2) Audit Report The company's Q1 2022 report is unaudited - The company's first quarterly report is unaudited[32]